Kangtai Bio faces share reduction amid bond conversion updates

Shenzhen Kangtai Biological Products is navigating a period of shareholder adjustments and convertible bond activity. According to a recent filing, shareholder Yuan Liping plans to reduce their holdings by up to 11.16 million shares, representing 1% of the company's total share capital, to meet personal funding needs. The reduction will be done through either centralized bidding or block trading. This development occurs as Kangtai Bio also announced its convertible bond, "康泰转2 (Kangtai Convert 2, SZSE:123119)," conversion details for the second quarter of 2025. During this period, 103 bonds were converted, resulting in the issuance of 650 new shares. As of the end of the second quarter, the company has 19,990,043 convertible bonds remaining, representing a total remaining value of CNY 1,999,004,300. These changes come as the bond's conversion price remains at CNY 15.73 per share. A tracking rating report also highlights potential pressures on revenue and profit from market competition and cash flow concerns.